These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26493284)

  • 1. Mutations in genes encoding PI3K-AKT and MAPK signaling define anogenital papillary hidradenoma.
    Pfarr N; Sinn HP; Klauschen F; Flechtenmacher C; Bockmayr M; Ridinger K; von Winterfeld M; Warth A; Lorenz K; Budczies J; Penzel R; Lennerz JK; Endris V; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Feb; 55(2):113-9. PubMed ID: 26493284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
    Liau JY; Lan J; Hong JB; Tsai JH; Kuo KT; Chu CY; Sheen YS; Huang WC
    Hum Pathol; 2016 Sep; 55():57-62. PubMed ID: 27184479
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Goto K; Maeda D; Kudo-Asabe Y; Hibiya T; Hayashi A; Fukayama M; Ohashi K; Goto A
    J Clin Pathol; 2017 May; 70(5):424-427. PubMed ID: 27742746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.
    Pfarr N; Allgäuer M; Steiger K; Weichert W; Schirmacher P; Noske A; Stenzinger A
    Pathology; 2019 Jun; 51(4):362-368. PubMed ID: 31010589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.
    Volckmar AL; Leichsenring J; Flechtenmacher C; Pfarr N; Siebolts U; Kirchner M; Budczies J; Bockmayr M; Ridinger K; Lorenz K; Herpel E; Noske A; Weichert W; Klauschen F; Schirmacher P; Penzel R; Endris V; Stenzinger A
    Genes Chromosomes Cancer; 2017 Jan; 56(1):11-17. PubMed ID: 27438523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor.
    Konstantinova AM; Vanecek T; Martinek P; Kyrpychova L; Spagnolo DV; Stewart CJR; Portelli F; Michal M; Kazakov DV
    Ann Diagn Pathol; 2017 Jun; 28():12-18. PubMed ID: 28648934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
    Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
    Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
    Konstantinova AM; Shelekhova KV; Imyanitov EN; Iyevleva A; Kacerovska D; Michal M; Kazakov DV
    Am J Dermatopathol; 2017 May; 39(5):358-362. PubMed ID: 28291131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma.
    Lubin D; Toorens E; Zhang PJ; Jaffer S; Baraban E; Bleiweiss IJ; Nayak A
    Am J Surg Pathol; 2019 Jul; 43(7):1005-1013. PubMed ID: 31094929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
    Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
    Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
    Je EM; An CH; Yoo NJ; Lee SH
    APMIS; 2012 Aug; 120(8):635-9. PubMed ID: 22779686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
    van den Hurk K; Balint B; Toomey S; O'Leary PC; Unwin L; Sheahan K; McDermott EW; Murphy I; van den Oord JJ; Rafferty M; FitzGerald DM; Moran J; Cummins R; MacEneaney O; Kay EW; O'Brien CP; Finn SP; Heffron CC; Murphy M; Yela R; Power DG; Regan PJ; McDermott CM; O'Keeffe A; Orosz Z; Donnellan PP; Crown JP; Hennessy BT; Gallagher WM
    Melanoma Res; 2015 Jun; 25(3):189-99. PubMed ID: 25746038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.